NCT03809559 is a clinical trial of MRCP+ in Primary Sclerosing Cholangitis, sponsored by Perspectum.

Who is sponsoring NCT03809559?

NCT03809559 is sponsored by Perspectum.

What drugs are being tested in NCT03809559?

Interventions in NCT03809559: MRCP+.

What condition does NCT03809559 study?

NCT03809559 studies Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Gallstones, Liver Diseases.

Is NCT03809559 still recruiting?

NCT03809559 is currently completed. Last updated 28 August 2019.

Last reviewed 2019-08-28 · How we verify

NCT03809559

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Repeatability and Reproducibility of Quantitative MRCP

Completed Last updated 28 August 2019

What this trial tests

trial testing MRCP+ in Primary Sclerosing Cholangitis in 40 participants. Completed in 8 March 2019.

Timeline

19 July 2018

Primary endpoint
8 September 2018

8 March 2019

Quick facts

Lead sponsor	Perspectum
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	19 July 2018
Primary completion	8 September 2018
Estimated completion	8 March 2019
Sites	2 locations across United Kingdom

Drugs / interventions tested

MRCP+

Conditions studied

Primary Sclerosing Cholangitis — all drugs for Primary Sclerosing Cholangitis →
Primary Biliary Cirrhosis — all drugs for Primary Biliary Cirrhosis →
Gallstones — all drugs for Gallstones →
Liver Diseases — all drugs for Liver Diseases →

Sponsor

Perspectum

Who can join

18 and older, any sex, with Primary Sclerosing Cholangitis or Primary Biliary Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine the repeatability and reproducibility of Quantitative Magnetic Resonance Cholangiopancreatography (MRCP). Imaging scientists at Perspectum Diagnostics have developed a hessian-based mathematical model to enhance conventional MRCP to a 3D geometric model of the biliary tree, 'Quantitative MRCP'. This enables advanced quantitative measurement of bile duct width, orientation, branching point and curvative metrics. The technology has been validated against 3D printed phantoms for accuracy, and early clinical research has demonstrated the technology has potential for clinical impact, with improvement in radiologist performance versus conventional non-enhanced MRCP imaging (Vikal et al 2017). Quantitative MRCP aims to act as a tool to not only improve assessment of the current status of the biliary tree, but also act as a mechanism to track change within the ducts. Thus, it must be established that any change between scans is due to change in the physiology of the individual and not due to a quirk or fault of the technology. In order to achieve this a series of scans will be performed on an individual over a short period of time, for which the condition of the biliary tree within that individual can be assumed to be constant. Between each scan, subject and coil repositioning will occur. The study will recruit a group of adult volunteers, from both diseased groups and healthy groups in order to achieve a range of physiological biliary metrics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Primary Sclerosing Cholangitis

Currently open trials in the same condition.

NCT07229911 — A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) · Phase 1 · recruiting
NCT06905054 — Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation · Phase 2 · recruiting
NCT06455280 — A Study of SIPLIZUMAB in AILD and LT Patients · Phase 1 · recruiting
NCT06519162 — Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome · recruiting
NCT06351696 — The Effects of Bromelain Supplement in Patients With Ulcerative Colitis · NA · recruiting

Other Perspectum trials

Trials by the same sponsor.

NCT07098650 — Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System · recruiting
NCT04974710 — Developing an US-MRI Biomarker Fusion Model for Endometriosis · completed
NCT05326191 — First-trimester Placental Ultrasound Study · completed
NCT05000242 — West Hertfordshire Inflammatory Bowel Disease Technology Study · active not recruiting
NCT05110248 — Research and Development of Novel Quantitative Magnetic Resonance Imaging (MRI) Techniques in a Single Scan for Multiple · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03809559 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Perspectum
Last refreshed: 28 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03809559.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing